Date: 2014-09-22
Type of information: Licensing agreement
Compound: multidrug resistance protein 4 (MRP4/ABCC4) inhibitors, Ceefourin™ 1 and Ceefourin™
Company: Abcam (UK) Children’s Cancer Institute (Australia)
Therapeutic area:
Type agreement:
Action mechanism: MRP4 is a protein that belongs to the ATP-Binding Cassette (ABC) transporter superfamily of membrane pumps that export molecules from the cell. MRP4 effectively effluxes elements that are potentially toxic to the cell, protecting it from deleterious chemical build-ups and from xenobiotics, such as environmental toxins. Previous research on MRP4 and other ABC transporter family members has shown that these proteins are often ‘hijacked’ by cancer cells, which produce them at high levels to pump out chemotherapy drugs, effectively protecting the cancer cells from treatment. Multidrug resistance protein 4 (MRP4/ABCC4) inhibitors, Ceefourin™ 1 and Ceefourin™ 2, are potent, chemically distinct compounds. These compounds provide a complementary toolset for the research community, with the potential for enabling studies in the field to be more effective and insightful, and deliver results faster. Ceefourin™ 1 (ab145144) is a benzothiazol compound which potently and selectively inhibits MRP4-mediated substrate efflux. For example, Ceefourin 1 inhibits MRP4-mediated D-luciferin transport (IC50 = 1.5µM) as measured indirectly using a bioluminescence assay in HEK293-MRP4 cells with stable luciferase expression. Ceefourin 1 exhibits no detectable inhibition of other ABC transporters such as Pgp, ABCG2 and MRP1, MRP2, MRP3 and MRP5, and is non-toxic in normal fibroblast and cancer cell lines tested up to 50µM. Ceefourin™ 2 (ab145145) is a pyrazolopyrimidine compound which potently inhibits MRP4-mediated substrate efflux. It inhibits MRP4-mediated D-luciferin transport (IC50 = 7.0µM) as measured indirectly using a bioluminescence assay in HEK293-MRP4 cells with stable luciferase expression. Ceefourin 2 exhibits no detectable inhibition of other ABC transporters, such as Pgp, ABCG2 and MRP1, MRP2, MRP3 and MRP5. Ceefourin 2 displayed limited toxicity in two of eleven cancer cell lines tested up to 50µM, and exhibited no toxicity in two normal fibroblast lines tested to the same concentration. Ceefourin 2 shows metabolic stability (>30 min) in a mouse liver microsomal assay and limited acid-stability (half life < 2 hr at 37oC, pH 2). Ceefourin™ is a trademark of Children’s Cancer Institute. Ceefourin 1 and Ceefourin 2 are claimed under Australian provisional patent application 2014902472.
Disease:
Details: * On 22 September, 2014, Children’s Cancer Institute and Abcam plc, a global leader in the supply of life science research tools, have entered into an exclusive licence, supply and distribution agreement for multidrug resistance protein 4 (MRP4/ABCC4) inhibitors, Ceefourin™ 1 and Ceefourin™ 2, for research purposes. The first known selective inhibitors of MRP4, Ceefourin 1 and Ceefourin 2 are potent, chemically distinct compounds and represent important tools for investigating essential cellular processes such as multidrug resistance. The compounds will enable the further exploration of MRP4 function and have potential in development of therapeutic drugs to treat cancer. The novel MRP4 inhibitors were discovered and characterised by Children’s Cancer Institute. MRP4 is a protein that belongs to the ATP-Binding Cassette (ABC) transporter superfamily of membrane pumps that export molecules from the cell. MRP4 effectively effluxes elements that are potentially toxic to the cell, protecting it from deleterious chemical build-ups and from xenobiotics, such as environmental toxins. Previous research on MRP4 and other ABC transporter family members has shown that these proteins are often ‘hijacked’ by cancer cells, which produce them at high levels to pump out chemotherapy drugs, effectively protecting the cancer cells from treatment. Up to this point, researchers have not had access to effective MRP4 inhibitors without substantial confounding off-target effects. Highly specific research reagents are crucial to accurately defining how these proteins work. Furthermore, used together, these compounds provide a complementary toolset for the research community, with the potential for enabling studies in the field to be more effective and insightful, and deliver results faster. The licence agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
Financial terms:
Latest news:
